Second allogeneic transplants for multiple ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Second allogeneic transplants for multiple myeloma: a report from the ebmt chronic malignancies working party
Author(s) :
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Eikema, Dirk-Jan [Auteur]
Leiden University Medical Center [LUMC]
De Wreede, Liesbeth C. [Auteur]
Leiden University Medical Center [LUMC]
Koster, Linda [Auteur]
Leiden University Medical Center [LUMC]
Krger, Nicolaus [Auteur]
University Hospital Hamburg-Eppendorf
Einsele, Hermann [Auteur]
University Hospital of Würzburg
Minnema, Monique [Auteur]
University Medical Center [Utrecht] [UMCU]
Dominietto, Alida [Auteur]
Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria "San Martino" [IRCCS AOU San Martino]
Potter, Michael [Auteur]
The Royal Marsden
Passweg, Jakob R. [Auteur]
University Hospital Basel [Basel]
Bermudez, Arancha [Auteur]
Hospital Universitario Marqués de Valdecilla [Santander]
Nguyen-Quoc, Stéphanie [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Platzbecker, Uwe [Auteur]
University Hospital Leipzig = Universitätsklinikum Leipzig
Tischer, Johanna [Auteur]
University-Hospital Munich-Großhadern [München]
Ciceri, Fabio [Auteur]
IRCCS Ospedale San Raffaele [Milan, Italy]
Veelken, Joan Hendrik [Auteur]
Leiden University Medical Center [LUMC]
Ljungman, Per [Auteur]
Karolinska University Hospital [Stockholm]
Schaap, Nicolaas [Auteur]
Radboud University Medical Center [Nijmegen]
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Carella, Angelo Michele [Auteur]
Gandemer, Virginie [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Arcese, William [Auteur]
Università degli Studi di Roma Tor Vergata [Roma, Italia] = University of Rome Tor Vergata [Rome, Italy] = Université de Rome Tor Vergata [Rome, Italie]
Bloor, Adrian [Auteur]
The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
Olivieri, Attilio [Auteur]
Vincent, Laure [Auteur]
Hôpital Lapeyronie [CHU Montpellier]
Beksac, Meral [Auteur]
Ankara University School of Medicine [Turkey]
Schonland, Stefan O. [Auteur]
Heidelberg University Hospital [Heidelberg]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Trinity College Dublin
Eikema, Dirk-Jan [Auteur]
Leiden University Medical Center [LUMC]
De Wreede, Liesbeth C. [Auteur]
Leiden University Medical Center [LUMC]
Koster, Linda [Auteur]
Leiden University Medical Center [LUMC]
Krger, Nicolaus [Auteur]
University Hospital Hamburg-Eppendorf
Einsele, Hermann [Auteur]
University Hospital of Würzburg
Minnema, Monique [Auteur]
University Medical Center [Utrecht] [UMCU]
Dominietto, Alida [Auteur]
Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria "San Martino" [IRCCS AOU San Martino]
Potter, Michael [Auteur]
The Royal Marsden
Passweg, Jakob R. [Auteur]
University Hospital Basel [Basel]
Bermudez, Arancha [Auteur]
Hospital Universitario Marqués de Valdecilla [Santander]
Nguyen-Quoc, Stéphanie [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Platzbecker, Uwe [Auteur]
University Hospital Leipzig = Universitätsklinikum Leipzig
Tischer, Johanna [Auteur]
University-Hospital Munich-Großhadern [München]
Ciceri, Fabio [Auteur]
IRCCS Ospedale San Raffaele [Milan, Italy]
Veelken, Joan Hendrik [Auteur]
Leiden University Medical Center [LUMC]
Ljungman, Per [Auteur]
Karolinska University Hospital [Stockholm]
Schaap, Nicolaas [Auteur]
Radboud University Medical Center [Nijmegen]
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Carella, Angelo Michele [Auteur]
Gandemer, Virginie [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Arcese, William [Auteur]
Università degli Studi di Roma Tor Vergata [Roma, Italia] = University of Rome Tor Vergata [Rome, Italy] = Université de Rome Tor Vergata [Rome, Italie]
Bloor, Adrian [Auteur]
The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
Olivieri, Attilio [Auteur]
Vincent, Laure [Auteur]
Hôpital Lapeyronie [CHU Montpellier]
Beksac, Meral [Auteur]
Ankara University School of Medicine [Turkey]
Schonland, Stefan O. [Auteur]
Heidelberg University Hospital [Heidelberg]
Yakoub-Agha, Ibrahim [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Journal title :
Bone Marrow Transplantation
Abbreviated title :
Bone Marrow Transplant
Publication date :
2021-05-11
ISSN :
1476-5365
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse ...
Show more >The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.Show less >
Show more >The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:44:21Z
2024-01-31T10:40:45Z
2024-01-31T10:40:45Z
Files
- s41409-021-01286-x.pdf
- Non spécifié
- Open access
- Access the document